Bisantrene (RC220)
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Key Facts
About Race Oncology
Race Oncology is a specialty pharmaceutical company dedicated to the clinical development and commercialization of bisantrene, a drug with a unique dual mechanism of action combining DNA intercalation with inhibition of the fat mass and obesity-associated (FTO) enzyme. The company's primary focus is on acute myeloid leukemia (AML), targeting patient populations with poor prognoses, including those with relapsed/refractory disease and cardiac risk factors where bisantrene's reduced cardiotoxicity profile offers a potential advantage. Race is advancing bisantrene through clinical trials while exploring its potential in other solid and hematological malignancies. The company's strategy is built on securing intellectual property, generating robust clinical data, and pursuing strategic partnerships to maximize the value of its lead asset.
View full company profileAbout Race Oncology
Race Oncology is a specialty pharmaceutical company dedicated to the clinical development and commercialization of bisantrene, a drug with a unique dual mechanism of action combining DNA intercalation with inhibition of the fat mass and obesity-associated (FTO) enzyme. The company's primary focus is on acute myeloid leukemia (AML), targeting patient populations with poor prognoses, including those with relapsed/refractory disease and cardiac risk factors where bisantrene's reduced cardiotoxicity profile offers a potential advantage. Race is advancing bisantrene through clinical trials while exploring its potential in other solid and hematological malignancies. The company's strategy is built on securing intellectual property, generating robust clinical data, and pursuing strategic partnerships to maximize the value of its lead asset.
View full company profileAbout Race Oncology
Race Oncology is a specialty pharmaceutical company dedicated to the clinical development and commercialization of bisantrene, a drug with a unique dual mechanism of action combining DNA intercalation with inhibition of the fat mass and obesity-associated (FTO) enzyme. The company's primary focus is on acute myeloid leukemia (AML), targeting patient populations with poor prognoses, including those with relapsed/refractory disease and cardiac risk factors where bisantrene's reduced cardiotoxicity profile offers a potential advantage. Race is advancing bisantrene through clinical trials while exploring its potential in other solid and hematological malignancies. The company's strategy is built on securing intellectual property, generating robust clinical data, and pursuing strategic partnerships to maximize the value of its lead asset.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Imetelstat + Azacitidine ± Venetoclax | Geron | Phase 1/2 |